The MUSETTE trial found no additional benefit in higher doses of ocrelizumab for RMS compared to the standard 600 mg dose. The 600 mg dose of ocrelizumab remains optimal for slowing disability ...

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...

Ocrelizumab 920mg, hyaluronidase-ocsq 23000 Units; per 23mL; soln for SC inj; preservative-free. Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do ...

New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ocrelizumab provides superior control of ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational medicine ocrelizumab (OCREVUSTM ...

Women with multiple sclerosis (MS) who were treated with ocrelizumab (Ocrevus) had no increased risk of adverse pregnancy and infant outcomes, prospective data showed. Cumulative data did not suggest ...

Multiple sclerosis (MS) patients treated with ocrelizumab (Ocrevus) had a higher risk of infections over time than other MS patients, a real-world cohort study showed. The risk for serious infection ...

Please provide your email address to receive an email when new articles are posted on . No significant differences were found in risk for serious infection among ocrelizumab age groups.

(Barcelona, Spain, Wednesday, 24 September 2025) New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ...